-
Nillessen claims shock European 1,500m gold
-
Lala, now a hurricane, dumps heavy rain on Hawaii
-
Taylor scores two tries in winning debut as New Zealand captain
-
American Kate Douglass reclaims 50m freestyle world record
-
England defender Spence leaves Spurs for Inter Milan
-
Kit confusion disrupts Newcastle friendly against Leverkusen
-
Moore double leads Spurs to 3-0 friendly win over Hoffenheim
-
Marchand wins first Euros gold as Liebmann breaks 1500m free world record
-
Man Utd beaten by former boss Amorim's AC Milan in friendly finale
-
Zambia's vote marred by intimidation, counting pause: observers
-
Villagers evacuate as Belgium battles record wildfire
-
Marchand wins 200m butterfly for first Euros gold
-
Despite booming economy, young Moroccans still dream of Europe
-
Fernandez booed by Chelsea fans in friendly win over Sociedad
-
South Korea president proposes talks with North to formally end Korean War
-
Fans line Welsh streets as Bonnie Tyler body's returns for funeral
-
Residents evacuate as Belgium wildfire scorches 1,600 hectares
-
Tropical Storm Lala lashes Hawaii with heavy rain
-
easyJet strike sees 100 French flights cancelled
-
Lebanon reports 11 dead in strikes that Israel says targeted Hezbollah
-
Monica Bellucci and Florin Serban win at Locarno Film Festival
-
Crystal Palace sign Israel winger Khalaili
-
India's Padikkal hits unbeaten century in first Sri Lanka Test
-
Rescuers search for survivors as Indonesian quake death toll rises to 47
-
Liechtenstein places gender equality on its throne
-
Taliban govt supporters dance, take selfies in Kabul celebrations
-
Street rallies held as Taliban govt marks five years ruling Afghanistan
-
UK PM urges 'reflection' after Cambridge professor's death
-
World Cup winner Ferran Torres signs for PSG from Barcelona
-
Rescuers search for survivors as Indonesian quake death toll rises to 40
-
Monsoon rains submerge villages, fields in Myanmar
-
Earthquake rocks Spain's tourist jewel Granada
-
India's Padikkal, Rahul hit half-centuries in Sri Lanka Test
-
Perez, Fiorini set world records in winning Euro race walk golds
-
UK-based Afghan writer pleads for country's 'abandoned' women
-
Lebanon says 9 dead in strikes as Israel says targeted Hezbollah
-
Werro edges Hodgkinson in boost for world record-seeking 800m rivalry
-
World Cup winner Ferran Torres signs for Paris Saint-Germain
-
Mehidy claims Smith as Bangladesh sense historic upset in Australia
-
Disney reveals 'X-Men' cast, slate of sequels at D23 fan event
-
Indonesia rescuers search for survivors as quake death toll rises to 38
-
Star Cameroon goalkeeper Bihina faces Malawi's prolific Chawinga sisters in WAFCON final
-
Japan coach Jones says team should not get despondent after heavy loss
-
Mehidy claims Smith to keep Bangladesh on top in Australia Test
-
Flags, music as Taliban authorities mark five years ruling Afghanistan
-
Iran fires back at Trump's threat to declare Hormuz a US territory
-
'Like we were on a trampoline': Indonesia quake kills 20, thousands flee
-
No monkey business: India 'whisperers' guard world championships
-
Australia run riot to crush Japan 56-17 in Townsville
-
Steady India 101-1 at lunch in first Sri Lanka Test
Moderna Covid vaccine gets full US approval
The US Food and Drug Administration (FDA) announced Monday that it has granted full approval to Moderna's Covid-19 "Spikevax" vaccine, which had previously received an emergency use authorization in the United States.
"The public can be assured that Spikevax meets the FDA's high standards for safety, effectiveness and manufacturing quality required of any vaccine approved for use in the United States," acting FDA commissioner Janet Woodcock said in a statement.
"The FDA's approval of Spikevax is a significant step in the fight against the Covid-19 pandemic, marking the second vaccine approved to prevent Covid-19," Woodcock said.
The full approval of the Moderna vaccine is for individuals aged 18 or older.
A Pfizer vaccine for individuals aged 16 or older received full FDA approval at the end of August.
Woodcock said she hoped FDA approval of the Moderna vaccine "may instill additional confidence in making the decision to get vaccinated."
Moderna CEO Stephane Bancel called the FDA move a "momentous milestone" for the company.
"Our Covid-19 vaccine has been administered to hundreds of millions of people around the world, protecting people from Covid-19 infection, hospitalization and death," Bancel said in a statement.
The Moderna vaccine received an emergency use authorization in December 2020.
The full approval from the FDA concerns the first two doses of the Moderna vaccine. A booster dose remains under an emergency use authorization.
The FDA said clinical trials to determine the effectiveness of Spikevax included 14,287 vaccine recipients and 14,164 placebo recipients.
The most common side effects by clinical trial participants were pain at the injection site, fatigue, headaches, muscle or joint pain, chills, nausea or vomiting and swollen lymph nodes, the FDA said.
It said there was an increased risk in men aged 18 to 24 of myocarditis -- inflammation of the heart muscle -- and pericarditis -- inflammation of tissue surrounding the heart -- following vaccination with the second dose.
But, the FDA said, it has determined that the "benefits of the vaccine outweigh the risk of myocarditis and pericarditis in individuals 18 years of age and older."
S.F.Warren--AMWN